Because TJ102, which targets both CDH6 and FRα (Zhang J et al., 2025), and VBC108, which bispecifically targets CDH17 and CLDN18.2 (Wang W. V. et al., 2025), demonstrated efficacy in mouse models and tolerability in cynomolgus monkeys, TJ102 and VBC108 are anticipated to enter clinical trials in patients with solid tumors, especially ovarian cancer and gastric cancer, respectively. The gene discussed is CDH17; the disease is ovarian carcinoma.